IFNAR1 and melanoma: Collectively, our results suggest that the BRAFV600E mutation in melanoma, potentially by upregulating the IFNAR1/2, renders distinct susceptibility to antitumor therapies that induce IFN-1 pathway, such as the ICD-inducer PDT.